Terms: = Endocrine gland cancer AND ERBB4, MGC138404, 2066, ENSG00000178568, Q15303, p180erbB4, HER4 AND Treatment
24 results:
1. Systems biomarkers for papillary thyroid cancer prognosis and treatment through multi-omics networks.
Gulfidan G; Soylu M; Demirel D; Erdonmez HBC; Beklen H; Ozbek Sarica P; Arga KY; Turanli B
Arch Biochem Biophys; 2022 Jan; 715():109085. PubMed ID: 34800440
[TBL] [Abstract] [Full Text] [Related]
2. RNA-binding protein IGF2BP2 enhances circ_0000745 abundancy and promotes aggressiveness and stemness of ovarian cancer cells via the microRNA-3187-3p/erbb4/PI3K/AKT axis.
Wang S; Li Z; Zhu G; Hong L; Hu C; Wang K; Cui K; Hao C
J Ovarian Res; 2021 Nov; 14(1):154. PubMed ID: 34774079
[TBL] [Abstract] [Full Text] [Related]
3. Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations: Implications for future clinical trials in pancreatic cancer.
Khan T; Seddon AM; Dalgleish AG; Khelwatty S; Ioannou N; Mudan S; Modjtahedi H
Oncol Rep; 2020 Dec; 44(6):2581-2594. PubMed ID: 33125153
[TBL] [Abstract] [Full Text] [Related]
4. Combined Poziotinib with Manidipine treatment Suppresses Ovarian cancer Stem-Cell Proliferation and Stemness.
Lee H; Kim JW; Lee DS; Min SH
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33036254
[TBL] [Abstract] [Full Text] [Related]
5. Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial.
Coleman RL; Handley KF; Burger R; Molin GZD; Stagg R; Sood AK; Moore KN
Gynecol Oncol; 2020 May; 157(2):386-391. PubMed ID: 32037195
[TBL] [Abstract] [Full Text] [Related]
6. Discrepancy in calculated and measured glomerular filtration rates in patients treated with PARP inhibitors.
Zibetti Dal Molin G; Westin SN; Msaouel P; Gomes LM; Dickens A; Coleman RL
Int J Gynecol Cancer; 2020 Jan; 30(1):89-93. PubMed ID: 31792084
[TBL] [Abstract] [Full Text] [Related]
7. The prognostic significance of human epidermal growth factor receptor family protein expression in operable pancreatic cancer : HER1-4 protein expression and prognosis in pancreatic cancer.
Li Q; Zhang L; Li X; Yan H; Yang L; Li Y; Li T; Wang J; Cao B
BMC Cancer; 2016 Nov; 16(1):910. PubMed ID: 27871278
[TBL] [Abstract] [Full Text] [Related]
8. Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models.
Koussounadis A; Langdon SP; Um I; Kay C; Francis KE; Harrison DJ; Smith VA
BMC Cancer; 2016 Mar; 16():205. PubMed ID: 26964739
[TBL] [Abstract] [Full Text] [Related]
9. Review of our experience with neuroblastoma and ganglioneuroblastoma in adults.
Jrebi NY; Iqbal CW; Joliat GR; Sebo TJ; Farley DR
World J Surg; 2014 Nov; 38(11):2871-4. PubMed ID: 25002244
[TBL] [Abstract] [Full Text] [Related]
10. Flutamide and biomarkers in women at high risk for ovarian cancer: preclinical and clinical evidence.
Gruessner C; Gruessner A; Glaser K; AbuShahin N; Zhou Y; Laughren C; Wright H; Pinkerton S; Yi X; Stoffer J; Azodi M; Zheng W; Chambers SK
Cancer Prev Res (Phila); 2014 Sep; 7(9):896-905. PubMed ID: 24950779
[TBL] [Abstract] [Full Text] [Related]
11. Association between growth factor heregulin1α and receptors in growth of ovarian cancer cell line with high potentiality of peritoneal dissemination.
Nishiyama H; Soeda S; Watanabe T; Fujimori K
Fukushima J Med Sci; 2012; 58(1):22-32. PubMed ID: 22790889
[TBL] [Abstract] [Full Text] [Related]
12. Targeting EGFR in pancreatic cancer treatment.
Troiani T; Martinelli E; Capasso A; Morgillo F; Orditura M; De Vita F; Ciardiello F
Curr Drug Targets; 2012 Jun; 13(6):802-10. PubMed ID: 22458527
[TBL] [Abstract] [Full Text] [Related]
13. Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation.
Jiao Y; Ou W; Meng F; Zhou H; Wang A
Mol Cancer; 2011 Sep; 10():125. PubMed ID: 21962244
[TBL] [Abstract] [Full Text] [Related]
14. Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and her4 in benign and malignant ovarian tumors.
Steffensen KD; Waldstrøm M; Andersen RF; Olsen DA; Jeppesen U; Knudsen HJ; Brandslund I; Jakobsen A
Int J Oncol; 2008 Jul; 33(1):195-204. PubMed ID: 18575766
[TBL] [Abstract] [Full Text] [Related]
15. Evaluation of type 1 growth factor receptor family expression in benign and malignant thyroid lesions.
Wiseman SM; Griffith OL; Melck A; Masoudi H; Gown A; Nabi IR; Jones SJ
Am J Surg; 2008 May; 195(5):667-73; discussion 673. PubMed ID: 18424286
[TBL] [Abstract] [Full Text] [Related]
16. Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer.
Lafky JM; Wilken JA; Baron AT; Maihle NJ
Biochim Biophys Acta; 2008 Apr; 1785(2):232-65. PubMed ID: 18291115
[TBL] [Abstract] [Full Text] [Related]
17. Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment.
Wiseman SM; Masoudi H; Niblock P; Turbin D; Rajput A; Hay J; Bugis S; Filipenko D; Huntsman D; Gilks B
Ann Surg Oncol; 2007 Feb; 14(2):719-29. PubMed ID: 17115102
[TBL] [Abstract] [Full Text] [Related]
18. Ovarian granulosa cell tumors frequently express EGFR (Her-1), Her-3, and Her-4: An immunohistochemical study.
Leibl S; Bodo K; Gogg-Kammerer M; Hrzenjak A; Petru E; Winter R; Denk H; Moinfar F
Gynecol Oncol; 2006 Apr; 101(1):18-23. PubMed ID: 16330088
[TBL] [Abstract] [Full Text] [Related]
19. 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth.
Takai N; Jain A; Kawamata N; Popoviciu LM; Said JW; Whittaker S; Miyakawa I; Agus DB; Koeffler HP
Cancer; 2005 Dec; 104(12):2701-8. PubMed ID: 16265675
[TBL] [Abstract] [Full Text] [Related]
20. Mechanisms of resistance to Erbitux (anti-epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells.
Arnoletti JP; Buchsbaum DJ; Huang ZQ; Hawkins AE; Khazaeli MB; Kraus MH; Vickers SM
J Gastrointest Surg; 2004 Dec; 8(8):960-9; discussion 969-70. PubMed ID: 15585383
[TBL] [Abstract] [Full Text] [Related]
[Next]
